CanSino Biologics Inc. (688185.SS)
CNY 63.42
(0.21%)
CNY 63.42
(0.21%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 345.18 Million | 1.03 Billion | 4.29 Billion | 18.54 Million | 2.28 Million | 1.13 Million |
| Cost of Revenue | 1.22 Billion | 1.21 Billion | 1.29 Billion | 13.8 Million | 147.46 Thousand | 113.64 Million |
| Gross Profit | -876.01 Million | -186.6 Million | 3 Billion | 4.74 Million | 2.13 Million | -112.51 Million |
| Operating Expenses | 1.49 Billion | 1.26 Billion | 1.2 Billion | 445.06 Million | 204.2 Million | 152.35 Million |
| Selling, General and Administrative Expenses | 647.84 Million | 544.68 Million | 337.63 Million | 99.43 Million | 68.07 Million | 20.6 Million |
| Research and Development Expenses | 637.98 Million | 778.25 Million | 878.71 Million | 428.48 Million | 151.74 Million | 113.64 Million |
| Other Expenses | 199.8 Million | -60.97 Million | -14.99 Million | -82.85 Million | -15.61 Million | 100 Thousand |
| Cost and Expenses | 2.38 Billion | 2.47 Billion | 2.49 Billion | 458.86 Million | 204.2 Million | 152.35 Million |
| Operating Income | -1.93 Billion | -1.36 Billion | 1.91 Billion | -440.32 Million | -202.07 Million | -138.57 Million |
| Interest Expense | 64.14 Million | 41.34 Million | 20.41 Million | 7.02 Million | 8.98 Million | - |
| Income Tax Expense | -11.45 Million | -219.24 Million | 29.7 Million | -38.14 Million | -3.65 Million | 12.94 Million |
| Earnings before Tax | -1.97 Billion | -1.18 Billion | 1.93 Billion | -396.63 Million | -156.76 Million | -138.28 Million |
| Net Income | -1.48 Billion | -964.75 Million | 1.91 Billion | -358.49 Million | -153.1 Million | -138.28 Million |
| Earnings Per Share Basic | -6.01 | -3.91 | 7.74 | -1.45 | -0.62 | -0.63 |
| Earnings Per Share Diluted | -6.01 | -3.91 | 7.74 | -1.45 | -0.62 | -0.63 |
| Weighted Average Shares Outstanding | 246.71 Million | 246.76 Million | 247.45 Million | 247.44 Million | 247.44 Million | 218.19 Million |
| Weighted Average Shares Outstanding (Diluted) | 246.71 Million | 246.76 Million | 247.45 Million | 247.44 Million | 247.44 Million | 218.19 Million |
| Gross Margin | -2.54 | -0.18 | 0.70 | 0.26 | 0.94 | -99.39 |
| EBIT Margin | -4.77 | -1.00 | 0.46 | -21.73 | -60.41 | -122.62 |
| Profit Margin | -4.30 | -0.94 | 0.45 | -19.33 | -67.05 | -122.16 |
| EBITDA | -1.64 Billion | -945.81 Million | 2.04 Billion | -364.68 Million | -134.24 Million | -126.26 Million |
| Earnings Before Tax Margin | -5.61 | -1.33 | 0.44 | -23.74 | -88.50 | -122.42 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 261.05 Million | 186.85 Million | 112.31 Million | 179.5 Million | 349.12 Million | 154.54 Million |
| Cost of Revenue | 54.83 Million | 75.55 Million | 46.23 Million | 116.93 Million | 370.95 Million | -624.85 Million |
| Gross Profit | 206.21 Million | 111.29 Million | 66.08 Million | 62.56 Million | -21.82 Million | 779.4 Million |
| Operating Expenses | 199.61 Million | 184.23 Million | 195.45 Million | 585.58 Million | 1.78 Billion | 291.5 Million |
| Selling, General and Administrative Expenses | 117.22 Million | 109.22 Million | 90.9 Million | 247.69 Million | - | 112.82 Million |
| Research and Development Expenses | 86.36 Million | 68.72 Million | 96.74 Million | 157.15 Million | - | 123.3 Million |
| Other Expenses | 3.98 Million | -6.27 Million | -7.8 Million | -180.74 Million | -602.42 Million | -8.33 Million |
| Cost and Expenses | 254.45 Million | 259.79 Million | 241.68 Million | 702.52 Million | 2.15 Billion | -333.35 Million |
| Operating Income | 6.6 Million | -72.94 Million | -129.37 Million | -523.01 Million | -1.8 Billion | 684.71 Million |
| Interest Expense | 14.68 Million | 18.04 Million | 14.67 Million | 18.18 Million | 64.14 Million | 16.68 Million |
| Income Tax Expense | 528 Thousand | 963.81 Thousand | 8.34 Million | -10.28 Million | -11.45 Million | 179.17 |
| Earnings before Tax | 3.53 Million | -51.24 Million | -161.75 Million | -524.01 Million | -1.98 Billion | -172.74 Million |
| Net Income | 2.96 Million | -55.27 Million | -170.09 Million | -497.7 Million | -1.48 Billion | -143.6 Million |
| Earnings Per Share Basic | 0.01 | -0.22 | -0.69 | -2.01 | - | -0.58 |
| Earnings Per Share Diluted | 0.01 | -0.22 | -0.69 | -2.01 | - | -0.58 |
| Weighted Average Shares Outstanding | 247.16 Million | 247.16 Million | 247.17 Million | 247.19 Million | 246.71 Million | 247.19 Million |
| Weighted Average Shares Outstanding (Diluted) | 247.16 Million | 247.16 Million | 247.17 Million | 247.19 Million | 246.71 Million | 247.19 Million |
| Gross Margin | 0.79 | 0.60 | 0.59 | 0.35 | -0.06 | 5.04 |
| EBIT Margin | 0.07 | -0.09 | -1.27 | -2.54 | - | 4.43 |
| Profit Margin | 0.01 | -0.30 | -1.51 | -2.77 | -4.25 | -0.93 |
| EBITDA | 18.22 Million | -16.54 Million | -143.06 Million | -455.78 Million | - | 684.71 Million |
| Earnings Before Tax Margin | 0.03 | -0.39 | -1.15 | -2.91 | -5.17 | 4.43 |
TRVN
PGRE
300651
600337
INCAF
6525